Search results
Results from the WOW.Com Content Network
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. [ 1 ] [ 2 ] It is used together with a diabetic diet and exercise.
Use during pregnancy and breastfeeding is not recommended. [3] It works predominantly by increasing the amount of insulin released from the pancreas. [1] It is classified as a second-generation sulfonylurea. [4] Glimepiride was patented in 1979 and approved for medical use in 1995. [5] It is available as a generic medication. [2]
[10] [8] Use in pregnancy and breastfeeding is not recommended. [10] Linagliptin is a dipeptidyl peptidase-4 inhibitor [8] that works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. [8] Linagliptin was approved for medical use in the United States, [11] Japan, the European Union, Canada, and ...
[4] [7] Use by those with significant kidney problems or liver problems or who are pregnant is not recommended. [7] [4] Gliclazide is in the sulfonylurea family of medications. [7] It works mostly by increasing the release of insulin. [7] Gliclazide was patented in 1966 and approved for medical use in 1972. [8]
Studies also show that the drug, scoring an 11 out of 12 as a gerotherapeutic, targets hallmarks of aging like cellular senescence by protecting DNA, decreasing inflammation, and improving insulin ...
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. [1] [2] Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
DPP-4 inhibitors and GLP-1. Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – was approved by the FDA in 2006. [1]